Understand the source comparison
SS-31 Before and After: Clinical vs Research Use Comparison
SS-31 before and after outcomes differ meaningfully between FDA-regulated clinical trials and research applications. Clinical trials operate under IND protocols with standardized dosing, defined endpoints, and rigorous adverse event monitoring. Research use. P
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- SS-31 before and after outcomes differ meaningfully between FDA-regulated clinical trials and research applications. Clinical trials operate under IND protocols with standardized dosing, defined endpoints, and rigorous adverse event monitoring. Research use. Particularly in academic or commercial labs. Prioritizes mechanistic insight over regulatory approval, allowing more flexible protocols but requiring researchers to source peptides from non-pharmaceutical suppliers and assume full responsibility for quality verification.
- Clinical Trials (STEALTH, EMBRACE)
- 0.25mg/kg SC daily, 28-day cycles, pharmaceutical-grade SS-31
- Six-minute walk distance, peak VO2, AKI incidence per KDIGO
- FDA-mandated batch testing, CoA for every lot, sterility verified
- Highest safety and consistency. Outcomes generalizable but access limited to trial participants
- Research Lab Use
- Variable. 0.1–1.0mg/kg, dosing frequency adjusted per experimental design
- Mitochondrial membrane potential, ROS production, ATP synthesis, cristae morphology
- Third-party HPLC/MS verification recommended, researcher-dependent sterility protocols
- Flexibility for novel applications. Requires rigorous internal validation to ensure peptide integrity
- Investigational Compounding
- Prescribed off-label under physician discretion, typically 4mg SC daily
- Patient-reported outcomes, biomarker panels (8-isoprostane, lactate), functional assessments
- Compounded by 503B facilities with USP standards, batch-specific CoA, not FDA-approved formulation
- Legal under shortage provisions. Same active molecule as pharmaceutical SS-31 but without full FDA oversight of final product
- The distinction between pharmaceutical-grade and research-grade SS-31 isn't the molecule. It's the manufacturing oversight. Pharmaceutical SS-31 (Elamipretide, formerly MTP-131) is produced under cGMP with validated synthesis, endotoxin testing below 0.5 EU/mL, and sterility assurance per USP <71>. Research-grade peptides from suppliers like Real Peptides undergo third-party purity verification but are sold for research purposes only, not human administration. The peptide sequence is identical. D-Arg-Dmt-Lys-Phe-NH2. But the regulatory pathway and quality documentation differ.
- For labs running SS-31 before and after studies, the critical control is peptide verification before use. Request a certificate of analysis showing ≥95% purity by HPLC and mass spectrometry confirmation of molecular weight (640.8 Da for SS-31). Endotoxin contamination is the silent experiment-killer. Even at sub-pyrogenic levels, endotoxin activates inflammatory pathways that confound mitochondrial readouts. Verify endotoxin testing was performed and results are below 1.0 EU/mg.